Apple Watch Blood Oxygen Tracking Returns For Series 9 And Later: What's New And How To Use It
The option to monitor your blood oxygen was big news when it arrived on Apple Watch Series 7 in 2021.
However, medical equipment manufacturer Masimo sued Apple in a patent dispute and in late 2023, Apple removed Series 9 and Ultra 2 watches from store shelves in the U.S. to comply with the dispute. They later returned with the app removed in early 2024 — though the hardware sensors remained unchanged.
Since the dispute only affected watches imported into the U.S., all models sold elsewhere in the world continued to have the feature, including on Series 10 models.
Apple released software updates on Aug. 14 which brought the app back in modified form to all affected models.
Apple Watch Blood Oxygen Tracking: The New Experience
Once you've updated your Apple Watch Series 9, Series 10 or Apple Watch Ultra 2 to the new watchOS 11.6.1 release and, crucially, your iPhone to iOS 18.6.1, you'll find the Blood Oxygen app is back, with the same app icon and instructions on how to use as before.
It's straightforward: sit upright with the watch resting flat and sit quietly for 15 seconds. An engaging animation will count you down. So far, so identical.
But where on models sold outside the U.S. the 15 seconds end with a chirp and a screen showing your blood oxygen percentage, now you're guided to discover the result on your iPhone.
It's in the Health app there, in the Respiratory section. It shows your range of results across your chosen interval and explanations of what the metric means. Again, this looks just like it always did in the Health app.
Apple Watch Blood Oxygen Tracking: What's Different
The new system takes raw data recorded on the Apple Watch and the calculation and expression of it is now done on the iPhone instead. This is the workaround that allowed Apple to bring the feature back.
Since the removal of the app on Series 9 and Ultra 2 began less than four months after they went on sale, millions of users for these watches and the newer Series 10 will now have access to a key health metric for the first time.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Bausch + Lomb board members resign after Icahn agreement ends
(Reuters) -Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates. The agreement, dated June 21, 2022, ended after the Icahn group's net long position in Bausch Health Companies, Bausch + Lomb's parent, fell below the required threshold. On Friday, Bausch Health said Paulson Capital, along with certain affiliates and managed funds, increased their position in the company and acquired about 34.7 million common shares previously held by the Icahn Group. In April, Carl Icahn had built an economic interest covering about 34% of Bausch Health's shares. Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
Vulcan Elements signs rare earths supply deal with ReElement Technologies
(Reuters) -Vulcan Elements, a North Carolina-based rare earth magnet manufacturer, has agreed to buy a supply of the critical minerals from ReElement Technologies that will be sourced outside of China. The companies, both of which are privately held, declined to give precise financial terms but said that the price is "significantly below" the floor of $110 per kilogram that the U.S. Department of Defense guaranteed to MP Materials last month for the two most popular rare earths. The contract was signed in mid-July, Vulcan said. Rare earth oxides are used to make metal that can then be turned into magnets for use in fighter jets, radar and other military applications, as well as consumer electronics. "This pricing will enable Vulcan to be competitive in global markets," Vulcan CEO John Maslin told Reuters. "We wanted to make sure the unit economics made sense." Indiana-based ReElement, which licenses its technology from Purdue University, will supply Vulcan with "thousands of metric tons" of rare earth oxides annually for five years beginning in 2026 from outdated electronics or from mine sites, said CEO Mark Jensen. ReElement says it can supply the rare earths to Vulcan below $110 per kilogram because of its use of a processing technique known as chromatography, which is different than the industry-standard solvent extraction used by many of its peers. "We are laser focused on cost," Jensen told Reuters. "We will see where the market goes, but right now we're focused more on the market price versus that price floor." Reuters was first to report last month that the Trump administration is considering extending that price floor to other firms, news that was relayed in a close-door Washington meeting attended by Vulcan, ReElement and others.
Geek Wire
10 minutes ago
- Geek Wire
Seattle health-tech startup Kevala acquired by Residex in bid to enhance senior care with AI
GeekWire's startup coverage documents the Pacific Northwest entrepreneurial scene. Sign up for our weekly startup newsletter , and check out the GeekWire funding tracker and venture capital directory . Todd Owens, CEO of Seattle-based health-tech startup Kevala. (Gavin Haag Photo) Seattle-based Kevala, a startup that helps healthcare facilities find and manage workers, has been acquired by Residex, a Denver company that also uses AI to manage records and more for senior living communities. Terms of the deal were not shared in a news release on Monday. Kevala was spun out of Seattle's Pioneer Square Labs in 2020. The company raisied $4 million in January 2021 and another $12.1 million in February 2022. Co-founder and CEO Todd Owens previously led staffing company TalentWise, which was acquired by Sterling Talent Solutions; was CEO at Appuri (acquired by DocuSign); and was CEO at Azuqua (acquired by Okta). According to Residex, the acquisition will strengthen the company's position in the senior care technology market by adding staffing optimization to platform. Residex uses AI to help manage resident health records, medication administration, care planning, assessments, and clinical documentation. Kevala's software, called Quin, enables healthcare facilities to schedule workers, organize the labor pool and track caregiver credentials. 'This acquisition validates our vision of using AI to solve the industry's most pressing operational challenge of ensuring topline workforce management,' Owens said in a statement. By combining Quin's workforce intelligence with Residex's clinical expertise, we're creating a powerful ecosystem that ultimately enhances the quality of life for residents.' As of April of this year, Kevala employed 28 people and had raised $21 million. Related:
